Success examples Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell Lymphoma Yu X., Liao X., Zhang J., Wang H., Li X., Lu J., Zhou H., Wu M., Jin Y., Zhu X., Xu L., Zeng S., Pan Y., Li J., Che J., Zhou Y., Dong X.J Med Chem. 2025, 68(19):20180-20206. BCL6 degrader Share page DOI PubMed
Success examples Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity Chen L., Liang Z., Mao J., Liao Z., Liu Y., Ou D., Liu C., Li Z.J Med Chem. 2025, 68(11):11127-11148. HSD17B13 inhibitor Share page DOI PubMed
Success examples Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID Shrestha S., Maitland M. E. R., Jing L., Duan S., Nie D. Y., St-Germain J., Barsyte-Lovejoy D., Arrowsmith C. H., Raught B.bioRxiv 2025, 14.648778. BRD7/BRD9 PROTAC SMARCA2 PROTAC Share page DOI
Success examples Oxidation of low-density lipoprotein by hemoglobin causes pulmonary microvascular endothelial barrier dysfunction through lectin-like oxidized LDL receptor 1 Meegan J. E., Riedmann K. J., Gonski S., Douglas J. S., Bogart A. M., Ware L. B., Bastarache J. A.Am J Physiol Lung Cell Mol Physiol. 2025, 328(5):L748-L755. LOX-1 inhibitor Share page DOI PubMed
General literature Empowering research in chemical biology and early drug discovery - an update from the European research infrastructure EU-OPENSCREEN Harmel R. K., Miletic T., Herzog K., Stechmann B.SLAS Discov. 2025, 32:100228. Share page DOI PubMed
Success examples The lung microvasculature promotes alveolar type 2 cell differentiation via secreted SPARCL1 Panza P., Kim H-T., Lautenschläger T., Piesker J., Günther S., Alayoubi Y., Cleaver O., Looso M., Stainier D. Y. R.Stem Cell Reports. 2025, 20(4):102451. IKKβ inhibitor Share page DOI PubMed
